Revolutionizing Cancer Care with Precision,
Low Toxicity, and Radiation-Activated Prodrugs.
Neoadjuvant Radiotherapy
It is performed before surgery with the aim of reducing the tumour size, which helps facilitate the subsequent surgery, or to provide patients who were originally inoperable with an opportunity to undergo surgery.
Curative Radiotherapy
The aim is to completely eliminate cancer cells and cure cancer. It is typically used for localised cancers, particularly in the early stages, or when surgery is not possible or the patient is unable to undergo surgery
How It Works—Radiotherapy-Activated Prodrug Therapy
Prodrug therapy operates on the principle of activating anticancer prodrugs through radiotherapy, which allows for the precise release and targeting of toxins within tumor cells. This method not only enhances the effectiveness of radiotherapy but also opens up a new field of precise synchronous radiotherapy and chemotherapy.
PolyAdvant's Key Advantages
Technical Feasibility: Our technical path is controllable and easy to implement, utilizing existing radiotherapy equipment as an energy source.
Platform Technology: Our platform technology offers significant value, with clinically validated precursor drugs and a clear clinical mechanism.
Overcoming Challenges in Cancer Treatment
Cancer treatment faces significant challenges, including the insensitivity of most tumors to radiation and the limitations of traditional chemotherapy. PolyAdvant addresses these challenges by:
Enhancing Radiation Sensitivity
Our prodrugs are designed to increase the sensitivity of tumors to radiation, broadening the applicability of radiotherapy.
Minimizing Side Effects
By localizing the release of toxins within tumors, we reduce the systemic adverse reactions associated with traditional chemotherapy.
Combating Drug Resistance
The combination of prodrugs and radiation therapy activates the immune response in the tumor microenvironment, reducing the likelihood of tumor recurrence.